The potential link between MAPK10 and immune activity in the TME of HCC, identified by this study, indicates that targeting MAPK10 in HCC might synergize with the therapeutic efficacy of T cell checkpoint antagonists such as PD-1 antibody. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.